Cancer52's Manifesto 'The Other Half'
Cancer52 has launched a manifesto called ‘The Other Half. A manifesto to transform outcomes for people with rare and less common...
top of page
Cancer52 Annual Review for 2022-2023
Cancer52 is proud to share its Annual Review for the financial year 2022-2023. As ever it is a great opportunity to look back at what has...
Cancer52 analysis on rare and less common cancer research spend
Cancer52 and the National Cancer Research Institute (NCRI) joined forces to create a report titled: Research into rare and less common...
A joint statement on the voluntary scheme for branded medicines pricing and access (VPAS)
Patient charities set out a shared vision for the next VPAS scheme. Cancer52 have joined forces with the Charity Medicines Access...
Cancer52 Annual Review 2021-2022
We are incredibly pleased to present our Annual Review for the financial year 2021-2022. It covers the period following the COVID-19...
Cancer52 launches inequalities report
Cancer52 are pleased to launch our report - Taking Action on Inequalities in Rare and Less Common Cancers: Understanding the Issues – at...
Showcase Video
From the start of the COVID-19 pandemic, we saw the incredible commitment of members in pulling out all the stops to meet the needs of...
2021 All Stakeholder Briefing Report
On Wednesday 13th October 2021, we hosted our Annual All Stakeholder Briefing, focusing on Early diagnosis for rare and less common...
Annual Review 2020-21
Cancer52 is delighted to present its Annual Review 2020-21. This report particularly highlights the strength and impact of Cancer52’s...
The impact of the Covid-19 pandemic on people with rare and less common cancers - Report published
Working with Keep up with Cancer[i] Cancer52 has published a new report which covers the impact of Covid-19 on people with rare and less...
bottom of page